screenshot pendingParcelBio is a biotechnology startup focused on developing advanced mRNA therapies aimed at addressing significant medical needs in autoimmune diseases, oncology, and therapeutic protein delivery. The company's proprietary platform, APEXm™ (Amplified and Prolonged EXpression mRNA), is designed to enhance the potency and durability of mRNA-based medicines, addressing limitations seen in conventional mRNA technologies. This innovative approach leverages the cell's native mechanisms to improve protein expression, allowing for a more robust therapeutic effect over extended periods.